Tempest Therapeutics
TPST
42 hedge funds and large institutions have $129M invested in Tempest Therapeutics in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
8% more capital invested
Capital invested by funds: $120M → $129M (+$9.24M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 45 → 42 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.53M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$1.32M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.01M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$684K |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.41M |
| 2 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$1.2M |
| 3 |
Jennison Associates
New York
|
-$424K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$377K |
| 5 |
Citigroup
New York
|
-$236K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $2K | – | – | – |
|
|
SIM
52
Spark Investment Management
New York
| – | -$180K | -7 | Closed |
|
|
CS
53
Credit Suisse
Zurich,
Switzerland
| – | -$106K | -4 | Closed |
|
54
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$47.2K | -2 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$14K | -1 | Closed |
|
56
Bank of America
Charlotte,
North Carolina
| – | -$1K | – | – |
|
TPST Hedge Fund Activity: Q2 2014 in Review
42 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2014, worth a combined $129M — up 7.7% from $120M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TPST and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 21 added.
The largest buyer was Adage Capital Partners, adding an estimated $1.53M. The largest seller was Sabby Management, cutting an estimated $1.41M.
- 42 institutional investors held Tempest Therapeutics (TPST) as of Q2 2014, down from 45 in Q1 2014.
- Funds reported $129M of Tempest Therapeutics stock for Q2 2014, up 7.7% quarter-over-quarter.
- 3 funds opened new Tempest Therapeutics positions in Q2 2014 and 6 closed out, a net change of -3 holders.
- The largest Tempest Therapeutics buyer in Q2 2014 was Adage Capital Partners, an estimated $1.53M added.
- The largest Tempest Therapeutics seller in Q2 2014 was Sabby Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q2 2014.